Regeneron stock holds after 2025 revenue and earnings growth

Regeneron (US75886F1075) stock is framed by 2025 revenue of $14.2 billion and net income of $4.4 billion, while the latest available market context points to a 52-week range that investors can use as a reference point.

2025 numbers still matter

Regeneron reported $14.2 billion in revenue for 2025, up from $13.1 billion in 2024, according to the company. Net income reached $4.4 billion in 2025, compared with $3.4 billion a year earlier, which gives the stock a clear earnings base even before any fresh catalyst is added.

The comparison is useful because it shows both top-line and bottom-line expansion in the same fiscal year. For a large-cap biotech group, that combination tends to matter more than narrative alone.

$4.4 billion profit base

Operating income rose to $5.0 billion in 2025 from $4.0 billion in 2024, while gross profit was $12.4 billion in 2025 versus $11.2 billion a year earlier. Those figures point to a business that kept converting sales into profit at scale.

Research and development expense was $3.2 billion in 2025, compared with $2.8 billion in 2024, showing continued spending alongside growth. That mix is important for a company whose pipeline and commercial portfolio both drive valuation.

Pipeline and product depth

A product-led read is still relevant for Regeneron stock because its commercial base includes Eylea and Dupixent collaboration economics, which sit at the center of the companys earnings profile. The product mix helps explain why 2025 revenue and profit stayed high even as investment continued.

For investors, the core point is that Regenerons 2025 figures provide a durable reference: revenue of $14.2 billion, net income of $4.4 billion, and operating income of $5.0 billion. That is the numerical backdrop against which any new report, trial update, or market move will be judged.

Market range reference

The stock line can be read against the latest market frame of a 52-week range, which gives context even when a same-day quote is not used here. The business case remains tied to whether earnings growth can keep pace with development spending and patent-driven pressure over time.